Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abbvie (ABBV)
:ABBV
Holding ABBV?
Track your performance easily
ABBV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$153.58 - $207.32
Previous CloseN/A
Volume1.02M
Average Volume (3M)5.65M
Market Cap
$310.22B
Enterprise Value$413.77B
Total Cash (Recent Filing)$6.42B
Total Debt (Recent Filing)$36.44B
Price to Earnings (P/E)59.8
Beta0.24
Next Earnings
Jan 31, 2025EPS Estimate
2.99Last Dividend Ex-Date
Jan 15, 2025Dividend Yield3.53%
Share Statistics
EPS (TTM)2.87
Shares Outstanding1,767,140,400
10 Day Avg. Volume5,243,057
30 Day Avg. Volume5,654,220
Standard Deviation0.07
R-Squared0.19
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.45
Price to Cash Flow (P/CF)13.90
P/FCF Ratio13.20
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue7.45
Enterprise Value/Gross Profit12.20
Enterprise Value/Ebitda22.73
Forecast
1Y Price Target
$203.06Price Target Upside16.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
AbbVie News
Bulls Say, Bears Say
Bulls Say
Aesthetics MarketABBV is a dominant player in the global aesthetics market, with long-term revenue guidance of over $9 billion indicating potential market recovery and new product launches.
Financial PerformanceThe company's strong leadership and good judgment provide a positive outlook for future growth, with momentum for Skyrizi and Rinvoq demonstrating robust demand.
ValuationThe current valuation of AbbVie is seen as an increasingly attractive entry point after a recent share pullback, suggesting confidence in its future performance.
Bears Say
Earnings ImpactThe estimated IPR&D EPS impact of $0.88 is leading to a decrease in the 4Q24E EPS by 29%.
Market PerformanceManagement lowered 2024 aesthetics guidance to $5.3 billion from $5.5 billion, with a notable reduction in Juvederm sales expectations.
Product Development ChallengesAbbVie announced that emraclidine’s pivotal Phase 2 trials did not meet their primary endpoints, spotlighting challenges in the schizophrenia drug market.
---
Ownership Overview
0.08% Insiders
21.89% Mutual Funds
0.66% Other Institutional Investors
56.89% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $153.58 and its highest was $207.32 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $310.22B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jan 31, 2025 which is in 13 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Oct 30, 2024. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.08.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $6.286 which represents an annual dividend yield of 3.53%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 2.99.
How many shares outstanding does Abbvie have?
Abbvie has 1,767,140,400 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $3 in its last earnings report, beating expectations of $2.92. Following the earnings report the stock price went up 6.362%.
Which hedge fund is a major shareholder of Abbvie?
Among the largest hedge funds holding Abbvie’s share is Diamond Hill Capital Management Inc. It holds Abbvie’s shares valued at 260M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$203.06 (16.90% Upside)
$203.06 (16.90% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 344.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $310.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.48%
12-Months-Change
Fundamentals
Return on Equity
84.91%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
Abbvie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
ABBV Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong commercial, operational, and R&D execution with significant growth from its ex-HUMIRA platform, increased revenue and EPS guidance, and successful acquisition and integration of Cerevel Therapeutics. However, challenges remain with declining HUMIRA sales, aesthetic market headwinds, and competitive pressures on IMBRUVICA.Read More>---
ABBV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
ABBV Stock 12 Month Forecast
Average Price Target
$203.06
▲(16.90% Upside)
Technical Analysis
Merck & Company
―
Pfizer
―
Bristol-Myers Squibb
―
Eli Lilly & Co
―
Amgen
―
Gilead Sciences
―
Best Analysts Covering ABBV
1 Year
1 Year Success Rate
35/40 ratings generated profit
1 Year Average Return
+21.02%
reiterated a buy rating last month
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.02% per trade.
---